There are plenty of smart executives in the world, but they often make poor leaders. That’s because it takes both intelligence and maturity to excel at leadership. And when I say... Read more »
In any business, projects fail, but in biopharmaceuticals, the consequences of failure are especially damaging. Projects in the industry tend to be long and expensive—from clinical trials to regulatory approvals to... Read more »
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars